Sanofi Global Health introduces Impact. (Credit: Melany @ tuinfosalud.com on Unsplash)
French pharmaceutical firm Sanofi, through its non-profit unit Sanofi Global Health, has introduced a new brand of standard of care medicines, dubbed Impact.
Impact is dedicated to enabling 30 critical medicines produced by the company, to be distributed to at-risk populations across 40 lower-income countries.
It includes insulin, glibenclamide and oxaliplatin, and other medicines to fight a wide range of areas including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.
The medicines offered under the Impact are on the World Health Organization (WHO) essential medicines list, said Sanofi.
Sanofi chief executive officer Paul Hudson said: “At Sanofi, we believe we have a responsibility to make a difference for the health of those most in need, and we know we have the ability and the ambition to bring about lasting change.
“With critical medicines, relentless drive and impactful partnerships, we can take our innovation beyond the lab and use it to strengthen health systems and access to medicines for those most vulnerable communities of patients.
“Sanofi Global Health aims to improve the lives of millions of people who now cannot get the help they need. Sanofi’s renewed purpose is to chase the miracles of science to improve people’s lives.”
Impact will serve countries in Africa, from Niger to Zimbabwe, conflict-hit countries such as Syria, along with Asian countries including Cambodia and Myanmar.
The launch of Impact follows the formation of Sanofi Global Health last year, which aims to increase access to healthcare through the distribution of medicines in low-income countries.
Sanofi Global Health forms one of the three elements of the company’s multi-tiered approach to social impact, alongside Foundation S, and CSR strategy.
Furthermore, Sanofi also intends to establish a $25m Impact fund to support start-up companies and others to develop scalable healthcare solutions, reported Reuters.
Sanofi global health unit head Jon Fairest: “The launch of the Impact brand and our Impact Fund are our latest steps to make our medicines available and to help bring quality, sustainable healthcare to people in the world’s poorest countries.
“But we know that we cannot do this alone, and so we are building partnerships at global, regional and local levels that will help to improve and establish health systems to reach our goal of a healthier, more resilient world.”
